JAMP GRANISETRON TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
13-01-2020
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
GRANISETRON (GRANISETRON HYDROCHLORIDE)
可用日期:
JAMP PHARMA CORPORATION
ATC代码:
A04AA02
INN（国际名称）:
GRANISETRON
剂量:
1MG
药物剂型:
TABLET
组成:
GRANISETRON (GRANISETRON HYDROCHLORIDE) 1MG
给药途径:
ORAL
每包单位数:
15G/50G
处方类型:
Prescription
治疗领域:
5-HT3 RECEPTOR ANTAGONISTS
產品總結:
Active ingredient group (AIG) number: 0123183001; AHFS:
授权状态:
APPROVED
授权日期:
2018-02-02
产品特点
PRODUCT MONOGRAPH
Pr
JAMP Granisetron
Granisetron Hydrochloride Tablets
1 mg granisetron (as granisetron hydrochloride)
Manufacturer Standard
Antiemetic
(5-HT
3
receptor antagonist)
Jamp Pharma Corporation
1310 rue Nobel
Boucherville, Québec
Canada J4B 5H3
Submission Control No.: 234371
DATE OF REVISION:
January 13, 2020
JAMP Granisetron
Page 2 of 25
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
..................................................................................................3
WARNINGS AND PRECAUTIONS
.................................................................................4
ADVERSE REACTIONS
..................................................................................................6
DRUG INTERACTIONS
..................................................................................................9
DOSAGE AND
ADMINISTRATION................................................................................9
OVERDOSAGE
..............................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 10
STORAGE AND
STABILITY.........................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 13
PART II: SCIENTIFIC
INFORMATION............................................................................
14
PHARMACEUTICAL
INFORMATION..........................................................................
14
CLINICAL TRIALS
........................................................................................................
14
DETAILED PHARMACOLOGY
..........
阅读完整的文件
